PREDICTING BRAIN TUMOR CHEMOSENSITIVITY BY IN VIVO MRS

通过体内 MRS 预测脑肿瘤化疗敏感性

• 批准号: 6514186
• 负责人: RAMON GILBERTO GONZALEZ
• 金额: $ 25.36万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2004-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6514186
• 关键词: astrocytoma; bioimaging /biomedical imaging; brain circulation; brain neoplasms; clinical research; functional magnetic resonance imaging; glioma; human subject; human therapy evaluation; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer genetics; phenotype; prognosis

The overall goal of this project is to investigate the use of MR spectroscopic and functional imaging methods to predict and assess chemotherapeutic response in brain tumors. Specifically, this work proposes to ascertain if new MR neuro-imaging techniques can discriminate between response and non-response to PCV chemotherapy in patients with anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). AO and AOA are unique in their chemosensitivity with approximately three-quarters of these tumors responding dramatically to the PCV regimen. Our preliminary studies show three major findings: 1) specific loss of chromosome 1p and 19q is strongly correlated with chemotherapeutic response in AO; 2) different tumor types give rise to quantifiable differences in the MRS metabolic pattern; 3) ex vivo MRS results accurately reflect in vivo MRS metabolic patterns. The discovery of the unique genetic correlates of chemosensitivity in AO and AOA presents a singular opportunity to investigate the relationship between genetics, MR detected metabolic phenotypes and chemotherapeutic response. We therefore hypothesize that metabolic and physiological MR imaging techniques can identify non-responsive tumors at an earlier time point than conventional imaging modalities. The following specific aims are designed to test this hypothesis: 1) To correlate in vivo and ex vivo MRS patterns and molecular genetics as predictors of response in untreated AO and AOA. 2) To characterize the in vivo spectroscopic patterns, rCBV maps and diffusion properties of AO and AOA prior to treatment and at specific time points during the initial cycle of chemotherapy. 3) To determine the relationship between MR metabolic, functional imaging and clinical response in patients with AO and AOA. The successful completion of this study will provide an assessment of the ability MR spectroscopic and functional imaging techniques to predict chemosensitivity prior to treatment and to monitor response throughout the therapy.

该项目的总体目标是研究使用磁共振波谱和功能成像方法来预测和评估脑肿瘤的化疗反应。具体地说，这项工作建议确定新的MR神经成像技术是否可以区分间变性少突胶质瘤(AO)和间变性少星形细胞瘤(AOA)患者对PCV化疗的反应和无反应。AO和AOA在化疗敏感性方面是独一无二的，其中约四分之三的肿瘤对PCV方案有显着反应。我们的初步研究发现：1)染色体1p和19q的特异性丢失与AO的化疗反应密切相关；2)不同的肿瘤类型导致MRS代谢模式的可量化差异；3)体外MRS结果准确地反映了体内MRS的代谢模式。AO和AOA独特的化疗敏感性遗传相关性的发现为研究遗传学、MR检测到的代谢表型和化疗反应之间的关系提供了一个难得的机会。因此，我们假设代谢和生理磁共振成像技术可以在比传统成像方法更早的时间点识别无反应肿瘤。为了验证这一假说，我们设计了以下特定目标：1)将体内和体外MRS模式和分子遗传学作为未经治疗的AO和AOA反应的预测因子。2)研究治疗前和化疗初期特定时间点的AO和AOA的体内波谱图、rCBV图和弥散特性。3)探讨AO和AOA患者的MR代谢、功能成像与临床反应的关系。这项研究的成功完成将对磁共振光谱和功能成像技术在治疗前预测化疗敏感性和监测整个治疗过程的反应的能力进行评估。

项目成果

Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

• 发表时间: 2004-02
• 期刊: AJNR. American journal of neuroradiology
• 作者: M. Lev;Y. Ozsunar;Y. Ozsunar;J. Henson;Amjad A Rasheed;G. Barest;G. Harsh;M. Fitzek;E. A. Chiocca;James D. Rabinov;Andrew N. Csavoy;B. Rosen;F. Hochberg;P. Schaefer;R. Gonzalez